Literature DB >> 2028230

Enhanced lymphoproliferation to influenza A virus following vaccination of older, chronically ill adults with live-attenuated viruses.

G J Gorse1, R B Belshe.   

Abstract

To question whether cellular immunity was stimulated by live-attenuated viruses in older, chronically ill adults, we intranasally inoculated 2 groups of volunteers (n = 37) with 2 different cold-recombinant, live-attenuated influenza A virus vaccines, and measured peripheral blood mononuclear cell responsiveness to influenza antigens and mitogen before and after vaccination. Lymphocyte proliferation to vaccine virus and to heterosubtypic influenza A virus increased postvaccination even in the subpopulation of vaccines who had a 4-fold nasal wash antibody titer rise to vaccine virus hemagglutinin, but no concomitant serum antibody titer rise to hemagglutinin. Vaccines aged greater than or equal to 65 years exhibited a rise in proliferation to vaccine virus postvaccination, as well. Based on lymphocyte proliferation, vaccine virus infection induced an enhanced cell-mediated immune response. Higher prevaccination serum antibody titers, however, were associated with protection from vaccine virus infection, and higher lymphocyte proliferation was not.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2028230     DOI: 10.3109/00365549109023368

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  7 in total

1.  Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses.

Authors:  Yo Han Jang; Young Ho Byun; Yoon Jae Lee; Yun Ha Lee; Kwang-Hee Lee; Baik Lin Seong
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

2.  Attenuated influenza virus construct with enhanced hemagglutinin protein expression.

Authors:  Jad Maamary; Natalie Pica; Alan Belicha-Villanueva; Yi-ying Chou; Florian Krammer; Qinshan Gao; Adolfo García-Sastre; Peter Palese
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

3.  HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials Network.

Authors:  G J Gorse; D H Schwartz; B S Graham; T J Matthews; D M Stablein; S E Frey; R B Belshe; M L Clements; P F Wright; M Eibl
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

Review 4.  Universal vaccination of healthy children against influenza: a role for the cold-adapted intranasal influenza vaccine.

Authors:  Robert M Jacobson; Gregory A Poland
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.

Authors:  Geoffrey J Gorse; Ramona E Simionescu; Gira B Patel
Journal:  Clin Vaccine Immunol       Date:  2006-01

6.  Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach.

Authors:  J Talon; M Salvatore; R E O'Neill; Y Nakaya; H Zheng; T Muster; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

Review 7.  Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines.

Authors:  Marine L B Hillaire; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  J Biomed Biotechnol       Date:  2011-10-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.